Maartje I Kester

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
    Argonde C van Harten
    Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands
    Clin Chem Lab Med 49:353-66. 2011
  2. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012
  3. doi request reprint Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 50:61-5. 2012
  4. doi request reprint CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    J Alzheimers Dis 16:601-7. 2009
  5. doi request reprint Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, The Netherlands
    Neurobiol Aging 32:1372-8. 2011
  6. doi request reprint Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:1083-90. 2010
  7. doi request reprint Diagnostic impact of CSF biomarkers in a local hospital memory clinic
    Maartje I Kester
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 29:491-7. 2010
  8. doi request reprint Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study
    Wesley Jongbloed
    Department of Clinical Chemistry, Neurological laboratory, VU University Medical Center, Amsterdam, The Netherlands
    Alzheimers Dement 9:276-83. 2013
  9. doi request reprint Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers
    Flora H Duits
    Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    J Alzheimers Dis 36:563-70. 2013
  10. doi request reprint Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:445-52. 2010

Collaborators

Detail Information

Publications10

  1. doi request reprint Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
    Argonde C van Harten
    Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands
    Clin Chem Lab Med 49:353-66. 2011
    ....
  2. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012
    ..Contrary to AD-specific markers, nonspecific CSF biomarkers, most notably isoprostane, showed change over time. These markers could potentially be used to monitor disease progression in AD...
  3. doi request reprint Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 50:61-5. 2012
    ..This study measured mRNA expression for nine of these promising bio-markers in 23 AD patients and 23 age- and sex-matched controls...
  4. doi request reprint CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    J Alzheimers Dis 16:601-7. 2009
    ..This suggests that cognitively healthy APOE epsilon4 carriers are more prone to develop AD pathology with aging. For AD patients, this provides support for the existence of subtypes within the disease...
  5. doi request reprint Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, The Netherlands
    Neurobiol Aging 32:1372-8. 2011
    ..To study CSF biomarkers amyloid-beta 1-42 (Aβ42) and total tau (tau) in relation to APOE genotype in their ability to predict progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD)...
  6. doi request reprint Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:1083-90. 2010
    ..Hypertension was not associated with Abeta42 levels, and APOE genotype did not modify this relation. Our findings suggest that hypertension is directly related to tau pathology in APOE epsilon4 homozygous carriers...
  7. doi request reprint Diagnostic impact of CSF biomarkers in a local hospital memory clinic
    Maartje I Kester
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 29:491-7. 2010
    ..We examined the impact of these biomarkers in the diagnostic process in a non-academic memory clinic...
  8. doi request reprint Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study
    Wesley Jongbloed
    Department of Clinical Chemistry, Neurological laboratory, VU University Medical Center, Amsterdam, The Netherlands
    Alzheimers Dement 9:276-83. 2013
    ....
  9. doi request reprint Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers
    Flora H Duits
    Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    J Alzheimers Dis 36:563-70. 2013
    ..Our results reiterate the importance of oxidative stress in neurodegeneration, especially in APOE ε4 carrying patients. Future studies should focus on the possibility of increased vulnerability to oxidative damage in APOE ε4 carriers. ..
  10. doi request reprint Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:445-52. 2010
    ..Our findings favor the implementation of CSF Abeta40 in differential diagnosis between FTLD, AD, and control subjects...